Skip to main content
Type at least 3 characters

390 articles

Original Research

Published on 11 Mar 2022

Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study

in Thoracic Surgery

  • Jing-Ren Ye
  • Pei-Hsing Chen
  • Jen-Hao Chuang
  • Mong-Wei Lin
  • Tung-Ming Tsai
  • Hsao-Hsun Hsu
  • Jin-Shing Chen
Frontiers in Surgery
doi 10.3389/fsurg.2022.816018
  • 2,900 views